Physician profile
Syed Abdul Basit
NPI 1942509492
$6,994.31
in general payments reported to CMS, 2019-2025
32 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $517 · 2021: $950 · 2022: $1,262 · 2023: $1,175 · 2024: $1,575 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,584 · Education: $91.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,583.79 |
| Education | $91.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,350.97 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $774.38 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $385.16 | 2019-2024 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.12 | 2021-2024 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $290.70 | 2019-2024 | |
| Genzyme Corporation | $287.62 | 2022-2025 | |
| Pfizer INC. | $202.41 | 2019-2025 | |
| Qol Medical, LLC | $164.79 | 2019-2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $144.01 | 2019-2024 | |
| Boston Scientific Corporation | $139.62 | 2019-2020 | |
| Braintree Laboratories, INC. | $113.68 | 2019-2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $84.62 | 2020-2023 | |
| Madrigal Pharmaceuticals | $82.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $75.91 | 2020-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $69.16 | 2019-2023 | Ocaliva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $68.32 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $57.02 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $44.61 | 2021-2023 | |
| Daiichi Sankyo INC. | $41.63 | 2019-2021 | |
| Shionogi INC | $36.68 | 2019 | |
| Lucid Diagnostics INC. | $29.72 | 2023 | |
| Orphalan INC | $28.10 | 2025 | Cuvrior |
| Biocon Biologics INC | $24.35 | 2025 | Yesintek |
| Biocompatibles, INC. | $22.73 | 2019 | |
| Celltrion USA INC. | $20.66 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $17.83 | 2024 | Voquezna |
| Lilly USA, LLC | $17.62 | 2025 | Omvoh |
| Astrazeneca Pharmaceuticals LP | $17.22 | 2023 | Andexxa |
| Alfasigma USA, INC. | $16.57 | 2021 | |
| Shire North American Group INC | $16.41 | 2019 | |
| Celgene Corporation | $13.74 | 2022 | |
| Medtronic, INC. | $12.76 | 2023 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Abdul Basit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.